superior rates of gene delivery

Symvivo’s bacTRL platform technology is a genetically-modified probiotic bacteria. Used as a single dose and administered intravenously or orally, bacTRL selectively colonizes hypoxic tissue while simultaneously being cleared from healthy tissues.

Throughout the life of the colony, the bacteria produce and deliver genetic material to the surrounding tissues, providing consistent and progressive levels of gene delivery and expression.

bacTRL Platform Diagram